Pfizer eyes ad agency work for cost-cutting

After a series of ad agency shuffles over the past several years, Pfizer ($PFE) is conducting an overall review of its agency work. But it's no garden-variety review: The RFP is part of the drugmaker's companywide, global cost-cutting efforts. Report